Hemostemix Closes CDN$280,594 Private Placement

Core Insights - Hemostemix Inc. has received conditional approval from the TSX Venture Exchange for a non-brokered private placement amounting to CDN $280,594, involving the issuance of 2,244,752 Common Shares at a price of CDN $0.125 per share [1][2] Company Overview - Hemostemix is a leading autologous stem cell therapy company, founded in 2003, specializing in VesCell™ (ACP-01) for various cardiovascular conditions [4] - The company has completed seven clinical studies involving 318 subjects, with results published in 11 peer-reviewed publications [4] - ACP-01 has shown significant clinical relevance and safety as a treatment for conditions such as peripheral arterial disease and chronic limb threatening ischemia, with a reported 0% mortality rate in a specific patient population over 4.5 years [4] Use of Proceeds - The proceeds from the private placement will be allocated to general working capital purposes, supporting ongoing operational expenses and business development activities [2] Regulatory Compliance - All securities issued in connection with the offering are subject to a four-month hold period under Canadian securities laws [3]